Daratumumab for Antibody-Mediated Rejection in Pediatric Kidney Transplant Recipients: A Single-Center Case Series (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1222; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "All recipients received pulse steroids and plasmapheresis; 3 received thymoglobulin, and 1 received rituximab for AMR treatment prior to daratumumab...Conclusion Daratumumab was well-tolerated and with significant improvement in DSA and almost complete resolution of inflammation, however clinical outcomes remained variable. Further investigation is warranted."
Clinical • Antibody-mediated Rejection • Infectious Disease • Inflammation • Pediatrics • Transplantation
|
|
Shanthi Sree Balani; Omar Mostafa; Chelsey Joy Jensen; Sarah J. Kizilbash
|